1. Home
  2. SATL vs CAPR Comparison

SATL vs CAPR Comparison

Compare SATL & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$7.95

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$30.24

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
CAPR
Founded
2010
2005
Country
United States
United States
Employees
154
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
SATL
CAPR
Price
$7.95
$30.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$5.50
$44.63
AVG Volume (30 Days)
7.9M
968.6K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$88.89
N/A
Revenue Next Year
$56.98
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$4.30
52 Week High
$8.90
$40.37

Technical Indicators

Market Signals
Indicator
SATL
CAPR
Relative Strength Index (RSI) 59.31 42.17
Support Level $3.17 $26.06
Resistance Level $8.18 $30.06
Average True Range (ATR) 0.75 2.12
MACD 0.06 -0.53
Stochastic Oscillator 69.81 19.86

Price Performance

Historical Comparison
SATL
CAPR

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: